Zanubrutinib Production Cost Reports

The report provides a detailed analysis essential for establishing a Zanubrutinib production plant. It encompasses all critical aspects necessary for Zanubrutinib production, including the cost of Zanubrutinib production, Zanubrutinib plant cost, Zanubrutinib production costs, and the overall Zanubrutinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Zanubrutinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Zanubrutinib is an oral medication that is used in the treatment of certain B-cell malignancies like mantle cell lymphoma (MCL) and other B-cell non-Hodgkin lymphomas. It works by irreversibly binding in the active site of BTK, which stops its kinase activity. This blocks the B-cell receptor (BCR), which is important for proliferation, survival, and adhesion. This leads to the death of malignant B-cells and suppression of tumour growth. It is administered orally and has improved specificity and reduced off-target effects compared to earlier BTK inhibitors.

It is suitable for patients who have relapsed or are refractory to prior treatments. Its common side effects include tiredness, diarrhoea, nausea, rash, infections, low blood counts (leading to bruising or anaemia), muscle/joint pain, or cough.

The market for Zanubrutinib is driven by its high efficacy and improved safety profile in treating various blood cancers. Its utilisation in mantle cell lymphoma, chronic lymphocytic leukaemia (CLL), and small lymphocytic lymphoma (SLL) fuels its market growth.

The rising prevalence of blood cancers, increasing adoption of targeted therapies, and ongoing clinical trials exploring combination therapies boost its demand. Its North American market is supported by strong healthcare infrastructure and regulatory support, while the Asia-Pacific is expanding because of enhanced healthcare access and pharmaceutical investments. The industrial Zanubrutinib procurement is affected by relapsed/refractory patient populations who require effective next-generation BTK inhibitors and physician preference for selective action with fewer side effects.

Raw Material for Zanubrutinib Production

According to the Zanubrutinib production plant project report, the key raw materials used in the production of Zanubrutinib include Benzoic Acid-Malononitrile-Trimethyl Orthoformate-(2-Aminopyrazole Derivative).

Production Process of Zanubrutinib

The extensive Zanubrutinib production cost report consists of the following major industrial production process:

1. From Benzoic Acid and Malononitrile: The production process of Zanubrutinib starts with the reaction of benzoic acid with malononitrile. The reactants are refluxed in ethyl acetate to form a vinyl dinitrile intermediate. This intermediate is methylated using trimethyl orthoformate in warm acetonitrile to generate an ether derivative. The corresponding 2-aminopyrazole is formed, which then reacts with a piperidine-containing keto aldehyde equivalent to produce a heterocyclic subunit. This is followed by hydrogenative saturation of the fused pyrimidine ring and acidic removal of the Boc protecting group to afford the piperidine bis(HCl) salt. Chiral salt resolution is performed to isolate the desired piperidine enantiomer. Finally, the tartrate salt goes through a reaction with acryloyl chloride under Schotten−Baumann conditions, which leads to the formation of Zanubrutinib.

Zanubrutinib has the molecular formula C27H29N5O3 and a molecular weight of 471.55 g/mol. It shows good solubility in DMSO, moderate in ethanol and DMF (10 mg/mL), with low water solubility. It has an XLogP3 value of 3.5-4.5, indicating moderately lipophilic, pKa of 3.33 (carboxylic acid) and 15.35 (predicted). It has 2 hydrogen bond donors, 5 acceptors, 6-7 rotatable bonds, topological polar surface area of 102-103 Ų. It features a pyrazolo[1,5-a]pyrimidine core with a piperidinyl-acryloyl warhead forming covalent bonds with Cys481, three hydrogen bonds to hinge residues. It has T-shape π-π stacking with Phe540, and water-mediated interactions, enabling high selectivity as a second-generation BTK inhibitor.